Saliva and remote monitoring of active Cytomegalovirus infection and symptoms during ovarian cancer treatment

Overview

About this study

The purpose of this project is to determine the feasibility and accuracy of using saliva to remotely monitor CMV infection in individuals receiving treatment for ovarian cancer.
 

Participation eligibility

Participant eligibility includes age, gender, type and stage of disease, and previous treatments or health concerns. Guidelines differ from study to study, and identify who can or cannot participate. There is no guarantee that every individual who qualifies and wants to participate in a trial will be enrolled. Contact the study team to discuss study eligibility and potential participation.

Inclusion Criteria:

  • Age ≥ 18.
  • Ability to read and write in English.
  • Diagnosed with ovarian cancer (ovarian, primary peritoneal, fallopian tube)
  • Receiving care from providers at the Mayo Clinic.
  • Regardless of diseases status, actively receiving treatment for ovarian cancer (frontline, maintenance, progression, recurrence).

Exclusion Criteria: 

  • Pregnant at the time of study participation.
  • Inability to provide informed written consent.
  • History of dementia, stroke, brain tumors or other condition which may impair their cognitive functioning.

Note: Other protocol defined Inclusion/Exclusion Criteria may apply.

Eligibility last updated 1/08/2025. Questions regarding updates should be directed to the study team contact.

Participating Mayo Clinic locations

Study statuses change often. Please contact the study team for the most up-to-date information regarding possible participation.

Mayo Clinic Location Status Contact

Rochester, Minn.

Mayo Clinic principal investigator

Amanika Kumar, M.D.

Contact us for the latest status

Contact information:

Cancer Center Clinical Trials Referral Office

(855) 776-0015

More information

Publications

Publications are currently not available
.
CLS-20580140

Mayo Clinic Footer